PERSONAL INFORMATION

Rebecca Romanò

POSITION

Medical Oncologist at Fondazione IRCCS Istituto Nazionale dei Tumori

EDUCATION AND TRAINING

Starts PhD in Biomedical Engineering at Politecnico di Milano.

2026 Starts working as Medical Oncologist at Fondazione IRCCS Istituto Nazionale dei Tumori, Milano – Thoracic Oncology Unit (Medical Oncology 1 Department).

2026 Master's degree at Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Milano: 70/70 cum laude

2025 Starts working at AI-ON Lab (Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Politecnico di Milano).

2020 Is awarded with "Luciana Costa" award 2020/2021 for Medicine and Surgery degree thesis in oncology.

Is awarded with "Premio Erminio Borloni" award 2020 for Medicine and Surgery degree thesis in radiotherapy or radiodiagnostics in oncology.

Collaborates with CNAO, Pavia (MI), supporting Direzione Scientifica and Clinical Trial Center (CTC) in the activities of implementation of clinical database

Successfully completes BLSD ADULTO PER OPERATORI SANITARI_ADDESTRAMENTO training program held by AREU (Milano)

Laurea Magistrale A Ciclo Unico in Medicina e Chirurgia (classe lm-41) International Medical School, Università degli Studi di Milano: 110/110 cum laude

2019 Participates to "Corso introduttivo al Primo Soccorso Pediatrico" (duration 2.5 hours) held by Rho Soccorso (ANPAS)

Participates to the course "Mendeley - English edition" held by Università degli Studi di Milano – Servizio Bibliotecario di Ateneo

Has successfully passed the training course (duration 4 hours) "Workers' General Training" Art. 37, D.Lgs. 81/2008 - Accordo Stato-Regioni 21/12/2011 - Accordo Stato-Regioni 07/07/2016 - European directive 89/391/EEC held by Associazione Italiana Formatori ed Operatori della Sicurezza sul lavoro (AiFOS)

2018 Participates in the ESMO-ESO Course on Medical Oncology for Medical Students, 2nd-7th September 2018, Naples, Italy

2014 Participates to elective course ''Inheritance and gastrointestinal tumors: from bench to bedside'' at Fondazione IRCSS Istituto Nazionale dei Tumori di Milano (coordinator G. Delconte, MD)

Diploma: General High School at Liceo Clemente Rebora, Rho (MI): 98/100

© European Union, 2002-2017 | europass.cedefop.europa.eu

PERSONAL SKILLS

Mother tongue(s): Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
	Certificate of Proficiency in English (Cambridge ESOL Level 3 Certificate in ESOL International)				

© European Union, 2002-2017 | europass.cedefop.europa.eu

Digital skills

Operating Systems Software: Windows - Skill level: excellent

Personal Interests

Music (alternative rock, jazz) and cinema
Classical and modern literature (in particular Russian) and poetry (M. De Angelis)
Cooking (plant-based) and travelling

Driving licence

B

PUBLICATIONS

Alfieri S, Romanò R, Bologna M et al. Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. *Acta Oncol. 2021 Sep;60(9):1192-1200. doi: 10.1080/0284186X.2021.1924401.*

Muraro E, Romanò R, Fanetti G et al. Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology. *Crit Rev Oncol Hematol. 2022 Jul;175:103707. doi: 10.1016/j.critrevonc.2022.103707.*

Taverna F, Alfieri S, Romanò R et al. Comparing BamHI-W and CE-marked assays to detect circulating Epstein-Barr Virus (EBV) DNA of nasopharyngeal cancer patients in a non-endemic area. *Oral Oncol. 2022 Dec;135:106229. doi: 10.1016/j.oraloncology.2022.106229.*

Denaro N, Romanò R, Alfieri S et al. The Tumor Microenvironment and the Estrogen Loop in Thyroid Cancer. *Cancers (Basel). 2023 Apr 25;15(9):2458. doi: 10.3390/cancers15092458.*

Pizzutilo EG, Romanò R, Roazzi L et al. Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity. *Cancer Res. 2023 May 19;CAN-23-0161. doi: 10.1158/0008-5472.CAN-23-0161.*

Bogani G, Cinquini M, Signorelli D et al. A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study. *Crit Rev Oncol Hematol. 2023 Jul;187:104016. doi: 10.1016/j.critrevonc.2023.104016.*

Pizzutilo EG, Agostara AG, Roazzi L et al. Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report. *JTO Clin Res Rep. 2023 Jul 26;4(11):100555. doi: 10.1016/j.jtocrr.2023.100555.*

Agostara AG, Roazzi L, Villa F et al. What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review. *Expert Rev Respir Med. 2023 Jul-Dec;17(9):787-803. doi: 10.1080/17476348.2023.2268509.*

Alfieri S, Romanò R, Marceglia S et al. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? *Oncologist. 2023 Dec 21:oyad319. doi: 10.1093/oncolo/oyad319.*

Romanò R, De Felice F, Ferri A et al. Adenoid Cystic carcinoma of minor salivary glands (AdCCmSG): a multidisciplinary update. *Expert Rev Anticancer Ther. 2024 Jul;24(7):567-580. doi: 10.1080/14737140.2024.2357806.*

Alfieri S, Romanò R, Marceglia S et al. Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study. *EJC. 2024 Jul. doi: 10.1016/j.ejca.2025.115625.*

Corso F, Peppoloni V, Mazzeo L et al. Combining Clinician Expertise with Prompt Engineering enhances Small Language Models Reliability for Cancer Entity Recognition in Electronic Health Records. *medRxiv 2025 Oct. doi: 10.1101/2025.10.16.25337917.*

© European Union, 2002-2017 | europass.cedefop.europa.eu

Alfieri S, Rota S, Romanò R et al. Alfieri S, Romanò R, Marceglia S et al. A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers. *ESMO Open 2026 Feb. doi: 10.1016/j.esmoop.2025.106033.*

Prelaj A, Provenzano L, Miskovic V, et al. APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer. *npj Precis. Onc. 2026 Jan. doi: 10.1038/s41698-026-01295-3.*

CONGRESSES AND GRANTS

Poster Presentation, “Multimodal AI Models Integrating Clinical and CT Imaging Data to Predict Survival Outcomes in Immunotherapy-Treated NSCLC: Results from the Multicentric APOLLO11 Study” European Lung Cancer Congress 2026

Poster Presentation, “Explainable Deep Learning for FDG PET/CT tumor detection: evaluation on a pan-cancer dataset,” ESMO AI & Digital Oncology Congress 2025

e-Poster Presentation, “Oncological Entity Recognition using Privacy-Preserving Large Language Models from Electronic Health Records” ESMO Congress 2025

Poster Presentation, “Association Between Tumor Longevity and Immune-Checkpoint Inhibitor outcomes: a retrospective study in Head and Neck, Lung, Renal/Urothelial cancers” ESMO Congress 2024

August 2025: winner as co-PI of Pfizer International LLC Competitive Grant Program – Exploring the Use of Artificial Intelligence (AI) Applications in ALK+ NSCLC with the research project: **XAI-Driven Identification of ALK fusions and Aggressive Phenotypes in ALK+ NSCLC – APOLLO11 Network Project (PI: Vanja Miskovic).**

© European Union, 2002-2017 | europass.cedefop.europa.eu